Biohaven Pharmaceutical Holding Co Ltd (BHVN NYSE) stock market data APIs
$8.2436
0.43(5.2%)
as of November 17, 2025
Try our APIs with
free plan!
Biohaven Pharmaceutical Holding Co Ltd Financial Data Overview
Price chart is built with
Anychart
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Prev. Close
8.2436
Open
8.6762
High
8.8688
Low
8.047
52 wk Range
7.48-47.75
Market Cap
1 097 M
Shares Outstanding
133 M
EPS
-1.64
Beta
3.453
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Biohaven Pharmaceutical Holding Co Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Biohaven Pharmaceutical Holding Co Ltd data using free add-ons & libraries
Get Biohaven Pharmaceutical Holding Co Ltd Fundamental Data
Biohaven Pharmaceutical Holding Co Ltd Fundamental data includes:
- Net Revenue:
- EBITDA: -771 865 024
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: -1.88
Get Biohaven Pharmaceutical Holding Co Ltd End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Biohaven Pharmaceutical Holding Co Ltd News
New
Carl Icahn Makes Another Huge Insider Purchase
Neilson Barnard / Getty Images Entertainment via Getty Images In the past week or so, beneficial owners Carl Icahn made a big bet on Centuri Holdings Inc. (NYSE: CTRI), his second significant purchas...
William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth
Biohaven Ltd. (NYSE:BHVN) is one of the best small-cap biotech stocks to buy according to analysts.William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth On Novembe...
Biohaven (BHVN): Assessing Valuation After $175 Million Stock Offering and FDA Setback
Biohaven (NYSE:BHVN) has completed a $175 million public stock offering, using the fresh capital to shore up its balance sheet. This funding round comes at a time when the company is navigating major ...
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
NEW HAVEN, Conn., Nov. 13, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
